Polypharmacy is associated with treatment response and serious adverse events: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rheumatology (United Kingdom)

Volumn 58, Issue 10, 2019, Pages 1767-1776

  Bechman, Katie ^a   Clarke, Benjamin D ^a   Rutherford, Andrew I ^a   Yates, Mark ^a   Nikiphorou, Elena ^a   Molokhia, Mariam ^b   Norton, Sam ^a   Cope, Andrew P ^a   Hyrich, Kimme L ^c,d   Galloway, James B ^a  

^a School of Immunology and Microbial Sciences   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Central Manchester Foundation Hospitals Trust   (United Kingdom)

Author keywords

biologics; outcome measures; polypharmacy; rheumatoid arthritis; serious adverse event

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; POLYPHARMACY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REGISTER; STATISTICAL MODEL; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYPHARMACY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; ROC CURVE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85072627812     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kez037     Document Type: Article

References (46)

1. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. Age Ageing 2018;47:220-5.
2. Smolen JS, Landewé R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
3. Ledingham J, Gullick N, Irving K et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology 2017;56:865-8.
4. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1-26.
5. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Rheumatol 2000;11:229.
6. Gonzalez A, Maradit Kremers H, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7.
7. Nikiphorou E, Norton S, Carpenter L et al. Secular changes in clinical features at presentation of rheumatoid arthritis: increase in comorbidity but improved inflammatory states. Arthritis Care Res 2017;69:21-7.
8. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61.
9. Smitten AL, Simon TA, Hochberg MC, Suissa S. A metaanalysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
10. Solomon DH, Goodson NJ, Katz JN et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
11. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:885-906.
12. Dougados M, Soubrier M, Antunez A et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
13. Wolfe F, Michaud K, Li T, Katz RS. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010;37:305-15.
14. England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res 2015;67:865-72.
15. O'Malley KJ, Cook KF, Price MD et al. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40(5 Pt 2):1620-39.
16. Cowie MR, Blomster JI, Curtis LH et al. Electronic health records to facilitate clinical research. Clin Res Cardiol 2017;106:1-9.
17. Filkova M, Carvalho J, Norton S et al. Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis. J Rheumatol 2017;44:1786-93.
18. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64 Suppl 4:iv42-3.
19. Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011;20:514-22.
20. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002;11:97-104.
21. Gnjidic D, Hilmer SN, Blyth FM et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989-95.
22. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
23. Au K, Reed G, Curtis JR et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
24. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemiol Drug Saf 2010;19:901-10.
25. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-25.
26. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
27. Veeren JC, Weiss M. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008-2015. J Pharm Health Serv Res 2017;8:5-11.
28. Davies EC, Green CF, Taylor S et al. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.
29. Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
30. Smitten AL, Choi HK, Hochberg MC et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93.
31. Nobili A, Licata G, Salerno F et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 2011;67:507-19.
32. Payne RA, Abel GA, Guthrie B, Mercer SW. The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: A retrospective cohort study. CMAJ 2013;185:E221-8.
33. Cherubini A, Eusebi P, Dell'Aquila G et al. Predictors of hospitalization in Italian nursing home residents: the U. L. I. S. S. E. project. J Am Med Dir Assoc 2012;13:84. e5-10.
34. Beer C, Hyde Z, Almeida OP et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: An observational study. Br J Clin Pharmacol 2011;71:592-9.
35. Perkins AJ, Kroenke K, Unü tzer J et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 2004;57:1040-8.
36. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 2006;12:110-9.
37. Treharne GJ, Douglas KM, Iwaszko J et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care 2007;5:175-90.
38. Gonzá lez-Gamboa LM, Barocio-Ram?rez AK, Rocha-Munõz AD et al. Disease activity score on 28 joints and polypharmacy are independent predictors for healthrelated quality of life evaluated by INCAVISA in patients with rheumatoid arthritis. J Clin Rheumatol 2016;22:399-404.
39. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008;46:72-83.
40. Avery AJ, Dex GM, Mulvaney C et al. Development of prescribing-safety indicators for GPs using the RAND Appropriateness Method. Br J Gen Pract 2011;61:e526-36.
41. American Geriatrics Society 2015. Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227-46.
42. Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: A population-based cohort study. Ann Pharmacother 2016;50:89-95.
43. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ1993;307:846-8.
44. Fischer MA, Stedman MR, Lii J et al. Primary medication non-adherence: Analysis of 195 930 electronic prescriptions. J Gen Intern Med 2010;25:284-90.
45. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
46. Hyrich K, Symmons D, Watson K, Silman A, and BSRBR Control Centre Consortium, on behalf of the British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2005;65:895-8.